Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIME Regimen Followed by Autologous Stem Cell Rescue in High Risk Lymphoma
NCT00006373Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Feb 2000
- Primary completion
- Oct 2006
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of topotecan liposome, ifosfamide, etoposide and mesna in non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL), sponsored by Moffitt Cancer Center. Primary endpoint: Progression-Free Survival at 3 years. Started Feb 2000; status: completed.
02
Drugs
topotecan liposomeifosfamideetoposidemesna
03
Conditions
non-Hodgkin lymphoma (NHL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00006373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006373.